Does the therapy with finerenone reduce the albuminuria in patients with diabetic nephropathy? Is the effect dose-dependant? The following article explored the questions.
Article name: Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy. A Randomized Clinical Trial
This article was published in JAMA in 2015. It is a randomized controlled trial (RCT):
The mean placebo-corrected ratios of UACR at day 90 vs baseline in the finerenone groups:
| Finerenone Dose | Mean placebo-corrected ratios of UACR at day 90 vs baseline | p |
|---|---|---|
| 7.5 mg | 0.79 | 0.004 |
| 10 mg | 0.76 | 0.001 |
| 15 mg | 0.67 | < 0.001 |
| 20 mg | 0.62 | < 0.001 |
Finerenone is a nonsteroidal, highly selective mineralocorticoid receptor antagonist (MRA) with a greater affinity for the mineralocorticoid receptor than eplerenone. The study was a RCT, double-blind, and placebo-controlled. Most of the patients of the study were already receiving RAS blockade. Finerenone reduced the placebo-corrected urine albumin/creatinine ratio (UACR) at day 90 in a dose-dependent manner, with a significant reduction in UACR ranging from 21% to 38% in the finerenone dosage groups of 7.5 to 20 mg/d compared with placebo